z-logo
open-access-imgOpen Access
H5N1 Clade 2.2 Polymorphism Tracing Identifies Influenza Recombination and Potential Vaccine Targets
Author(s) -
Henry L. Niman,
Magdi D. Saad,
Bruce R. Boynton,
Jeffery Tjaden,
Kenneth C. Earhart,
Moustafa Mansour,
Nasr El-Sayed,
A Nayei,
Ahmad S. Abdelghani,
Hala Essmat,
Elassai Labib,
Ehab Ayoub,
Mona M. Aly,
A.K. Arafa,
Marshall R. Monteville
Publication year - 2007
Publication title -
deleted journal
Language(s) - English
Resource type - Journals
ISSN - 9999-9999
DOI - 10.1038/npre.2007.553.1
Subject(s) - clade , influenza a virus subtype h5n1 , biology , hemagglutinin (influenza) , genetics , genetic diversity , serotype , gene , evolutionary biology , virology , phylogenetics , virus , population , demography , sociology
Highly pathogenic Influenza A H5N1 was first identified in Guangdong Province in 1996, followed by human cases in Hong Kong in 1997 1. The number of confirmed human cases now exceeds 300 and the associated Case Fatality Rate exceeds 60% 2. The genetic diversity of the serotype continues to increase. Four distinct clades or sub-clades have been linked to human cases 3.4. The gradual genetic changes identified in the sub-clades have been attributed to copy errors by viral encoded polymerases that lack an editing function, thereby resulting in antigenic drift 5. We traced polymorphism acquisition in Clade 2.2 sequences. We report here the concurrent acquisition of the same polymorphism by multiple, genetically distinct, Clade 2.2 sub-clades in Egypt, Russia and Ghana. These changes are not easily explained by the current theory of “random mutation” through copy error, and are more easily explained by recombination with a common source. This conclusion is supported by additional polymorphisms shared by Clade 2.2 isolates in Egypt, Nigeria and Germany including aggregation of regional polymorphisms from each of these areas into a single Nigerian human hemagglutinin gene

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here